Macular degeneration: recent advances and therapeutic opportunities.

Publisher: Nature Pub. Group Country of Publication: England NLM ID: 100962781 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1471-003X (Print) Linking ISSN: 1471003X NLM ISO Abbreviation: Nat Rev Neurosci Subsets: MEDLINE

Original Publication: London, UK : Nature Pub. Group,

Macular Degeneration/*physiopathology ; Retina/*physiopathology ; Retinal Artery/*physiopathology; Aging/metabolism ; Aging/pathology ; Animals ; Genetic Predisposition to Disease/genetics ; Humans ; Laser Therapy ; Macular Degeneration/genetics ; Macular Degeneration/therapy ; Nerve Tissue Proteins/genetics ; Nerve Tissue Proteins/metabolism ; Photoreceptor Cells, Vertebrate/metabolism ; Photoreceptor Cells, Vertebrate/pathology ; Pigment Epithelium of Eye/metabolism ; Pigment Epithelium of Eye/pathology ; Pigment Epithelium of Eye/physiopathology ; Retina/metabolism ; Retina/pathology ; Retinal Artery/pathology ; Retinaldehyde/antagonists & inhibitors ; Retinaldehyde/metabolism

The central retina mediates high acuity vision, and its progressive dysfunction due to macular degeneration is the leading cause of visual disability among adults in industrialized societies. Here, we summarize recent progress in understanding the pathophysiology of macular degeneration and the implications of this new knowledge for treatment and prevention. The past decade has witnessed remarkable advances in this field, including the development of new, non-invasive retinal imaging technologies, the development of animal models for macular disease, and the isolation of many of the genes responsible for both early- and late-onset macular diseases. These advances have set the stage for the development of effective mechanism-based therapies.

142

0 (Nerve Tissue Proteins)
RR725D715M (Retinaldehyde)

Date Created: 20061013 Date Completed: 20070105 Latest Revision: 20131121

20231215

10.1038/nrn2007

17033682